Allergy Asthma Immunol Res.  2012 Sep;4(5):305-308. 10.4168/aair.2012.4.5.305.

Clinical Features of Allergic Bronchopulmonary Aspergillosis in Korea

• Kim JH
• Jin HJ
• Nam YH
• Hwang EK
• Ye YM
• Park HS

• KMID: 2167050
• DOI: http://doi.org/10.4168/aair.2012.4.5.305

Abstract

Allergic bronchopulmonary aspergillosis (ABPA) is a complex disease, triggered by a hypersensitivity reaction to the allergen Aspergillus fumigatus. This disease occurs frequently in patients with cystic fibrosis and severe asthma in Western countries, with a prevalence of 2%-15%. However, there have been only a few case reports in Korea. We investigated the clinical and immunological features of patients with ABPA. Ten adult patients diagnosed with ABPA, according to Greenberger's criteria, were analyzed during the period January 2001 to December 2010 in a tertiary hospital. Skin-prick tests, pulmonary function tests, and high-resolution computed tomography (HRCT) were performed, and total serum IgE and A. fumigatus-specific IgE were measured. The patient cohort consisted of men who were middle-aged (median, 62.5; range, 19.0-79.0 years) at the diagnosis of ABPA with a long duration of asthma (median, 15.0; range, 1-48 years). Approximately 40% of the patients had a history of pulmonary tuberculosis more than 10 years prior to the study (median 23.5; range, 10.0-31.0 years) accompanied by severe obstructive lung function and radiological post-tuberculous destructive lung lesions. These patients also tended to have increased levels of immunologic parameters, such as total eosinophil count, total IgE, and A. fumigates-specific IgE, compared to those without tuberculosis sequels. Two patients with steroid-dependent asthma were treated with anti-IgE therapy and showed good responses. We report the clinical features of 10 ABPA patients, including 4 with histories of post-tuberculosis destructive lesions. Furthermore, anti-IgE antibody therapy may be an alternative strategy in cases of steroid-dependent ABPA.

Keyword

Allergic bronchopulmonary aspergillosis; asthma; tuberculosis; anti IgE antibody

MeSH Terms

Adult
Antibodies, Anti-Idiotypic
Aspergillosis, Allergic Bronchopulmonary
Aspergillus fumigatus
Asthma
Cohort Studies
Cystic Fibrosis
Eosinophils
Humans
Hypersensitivity
Immunoglobulin E
Korea
Lung
Male
Prevalence
Respiratory Function Tests
Tertiary Care Centers
Tuberculosis
Tuberculosis, Pulmonary
Antibodies, Anti-Idiotypic
Immunoglobulin E

Reference

1. Riscili BP, Wood KL. Noninvasive pulmonary Aspergillus infections. Clin Chest Med. 2009. 30:315–335. vii

2. Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol. 2002. 110:685–692.

3. Rosenberg M, Patterson R, Mintzer R, Cooper BJ, Roberts M, Harris KE. Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis. Ann Intern Med. 1977. 86:405–414.

4. Greenberger PA, Miller TP, Roberts M, Smith LL. Allergic bronchopulmonary aspergillosis in patients with and without evidence of bronchiectasis. Ann Allergy. 1993. 70:333–338.

5. Lee JS, Kim EC, Joo SI, Lee SM, Yoo CG, Kim YW, Han SK, Shim YS, Yim JJ. The incidence and clinical implication of sputum with positive acid-fast bacilli smear but negative in mycobacterial culture in a tertiary referral hospital in South Korea. J Korean Med Sci. 2008. 23:767–771.

6. Park JS. Korean guidelines for the treatment of tuberculosis. Korean J Med. 2012. 82:269–273.

7. Pasipanodya JG, Miller TL, Vecino M, Munguia G, Garmon R, Bae S, Drewyer G, Weis SE. Pulmonary impairment after tuberculosis. Chest. 2007. 131:1817–1824.

8. Smith NL, Denning DW. Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J. 2011. 37:865–872.

9. Ye F, Zhang NF, Zhong NS. Clinical and pathological analysis of allergic bronchopulmonary aspergillosis in China. Zhonghua Jie He He Hu Xi Za Zhi. 2009. 32:434–438.

10. Kudo K, Kabe J. Allergic bronchopulmonary aspergillosis (ABPA). Kekkaku. 1997. 72:91–98.

11. Maurya V, Gugnani HC, Sarma PU, Madan T, Shah A. Sensitization to Aspergillus antigens and occurrence of allergic bronchopulmonary aspergillosis in patients with asthma. Chest. 2005. 127:1252–1259.

12. Menzies D, Holmes L, McCumesky G, Prys-Picard C, Niven R. Aspergillus sensitization is associated with airflow limitation and bronchiectasis in severe asthma. Allergy. 2011. 66:679–685.

13. Lam KB, Jiang CQ, Jordan RE, Miller MR, Zhang WS, Cheng KK, Lam TH, Adab P. Prior TB, smoking, and airflow obstruction: a cross-sectional analysis of the Guangzhou Biobank Cohort Study. Chest. 2010. 137:593–600.

14. Lee SW, Kim YS, Kim DS, Oh YM, Lee SD. The risk of obstructive lung disease by previous pulmonary tuberculosis in a country with intermediate burden of tuberculosis. J Korean Med Sci. 2011. 26:268–273.

15. Elkington PT, Green JA, Emerson JE, Lopez-Pascua LD, Boyle JJ, O'Kane CM, Friedland JS. Synergistic up-regulation of epithelial cell matrix metalloproteinase-9 secretion in tuberculosis. Am J Respir Cell Mol Biol. 2007. 37:431–437.

16. Hilliard TN, Regamey N, Shute JK, Nicholson AG, Alton EW, Bush A, Davies JC. Airway remodelling in children with cystic fibrosis. Thorax. 2007. 62:1074–1080.

17. Kanu A, Patel K. Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab). Pediatr Pulmonol. 2008. 43:1249–1251.

18. Dimov VV, Casale TB. Immunomodulators for asthma. Allergy Asthma Immunol Res. 2010. 2:228–234.

19. Lin RY, Sethi S, Bhargave GA. Measured immunoglobulin E in allergic bronchopulmonary aspergillosis treated with omalizumab. J Asthma. 2010. 47:942–945.